|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Exclusive Content
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - preparing to underwrite what insiders are calling 'Project Apex.' A June timeline is now widely expected.
Dr. Mark Skousen, Macroeconomic Strategist at The Oxford Club, says nearly 15,000 investors have already found a 'backdoor' pre-IPO position - and he's sharing his top pick at no cost before the roadshow begins. Get Dr. Skousen's free SpaceX pre-IPO recommendation before the window closes
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in the last trading days of March. The sharp downturn has left many wondering whether the foundation of this industry leader is weakening. A closer look reveals a potential disconnect between market sentiment and operational reality, raising a key question: Is the market’s pessimism justified, or has a meaningful value opportunity opened up for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn't fall without cause. Its recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, driven primarily by market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a rotation of capital: in periods of economic optimism, investors often shift funds away from defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That broad trend has put pressure on many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment navigates a near-term recovery, Abbott's core businesses remain exceptionally strong, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model provides a powerful counterbalance to isolated weakness in Nutrition; the company’s health is most evident in these high-performing areas.
Medical Devices: This business is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth engine. The product line — which lets users track glucose levels without routine fingersticks — generated over $7.5 billion in sales in 2025 and is a primary driver of Abbott's sustained success. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, and its Structural Heart business posted strong organic growth of 8.7%. This strength stems from a portfolio of best-in-class products, such as MitraClip and TriClip, which offer minimally invasive heart valve repair solutions, and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal will immediately position Abbott in the rapidly expanding, multi-billion-dollar market for cancer diagnostics, adding a new, high-growth vertical that could become a significant revenue contributor for years to come. This bullish outlook is shared by analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of roughly 30% from current levels and signaling a belief that the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is especially compelling. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital to shareholders through all market cycles. The recent drop in Abbott’s stock price has a direct, positive effect for new investors: it increases the dividend yield. At current prices, Abbott yields about 2.5%, letting investors lock in a higher income rate from this historically reliable payer. The dividend is well supported: Abbott's payout ratio is roughly 68% of earnings, and the dividend represents only about 37% of operating cash flow, indicating ample cash generation to cover payments and leave room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from its business reality. Temporary headwinds in a single division and broader market rotations have depressed the stock, yet Abbott's fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver strong results, the dividend remains a bedrock of reliability, and strategic catalysts like the Exact Sciences acquisition add upside. For investors with a long-term perspective, the current valuation highlights a noteworthy gap between market price and fundamental value and may present a compelling opportunity worth serious consideration. |
